drugset / Trial / NCT02215538

OROS Methylphenidate (Concerta) in the Treatment of Adult ADHD

NCT02215538

RandomizedCrossoverTriple-blindTreatment

Summary

This study will look at the effectiveness of osmotic release oral system (OROS) methylphenidate (Concerta) in treating attention deficit hyperactvity disorder (ADHD) in adults. Concerta has received FDA approval for childhood ADHD and there is documentation that it is effective in adult ADHD. However this trial will explore its effectiveness in treating symptoms not a part of the Diagnostic and Statistical Manual-III (DSM-III) criteria. Subjects will experience one screening visit and one baseline visit. Those who meet admission criteria will enter the double-blind phase. This will involve two 4-week treatment periods one of which will involve the use of Concerta and the other a placebo pill. Subjects who complete the double-blind phase will be allowed to enter a 180-day, open-label Concerta phase designed to assess long-term effects.

Timeline

Start
2004-11
Primary completion
2006-02
Completion
2006-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylphenidate Small molecule